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Abstract
Recently we identified that PREX1 overexpression is critical for metastatic but not tumorigenic 
growth in a mouse model of NRAS-driven melanoma. In addition, a PREX1 gene signature 
correlated with and was dependent on ERK mitogen-activated protein kinase (MAPK) activation 
in human melanoma cell lines. In the current study, the underlying mechanism of PREX1 
overexpression in human melanoma was assessed. PREX1 protein levels were increased in 
melanoma tumor tissues and cell lines compared with benign nevi and normal melanocytes, 
respectively. Suppression of PREX1 by siRNA impaired invasion but not proliferation in vitro. 
PREX1-dependent invasion was attributable to PREX1-mediated activation of the small GTPase 
RAC1 but not the related small GTPase CDC42. Pharmacologic inhibition of ERK signaling 
reduced PREX1 gene transcription and additionally regulated PREX1 protein stability. This ERK-
dependent upregulation of PREX1 in melanoma, due to both increased gene transcription and 
protein stability, contrasts with the mechanisms identified in breast and prostate cancers, where 
PREX1 overexpression was driven by gene amplification and HDAC-mediated gene transcription, 
respectively. Thus, although PREX1 expression is aberrantly upregulated and regulates RAC1 
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activity and invasion in these three different tumor types, the mechanisms of its upregulation are 
distinct and context-dependent.
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INTRODUCTION
Driver roles in cancer have been identified for several members of the Dbl family of Rho 
guanine nucleotide exchange factors (RhoGEFs), most prominently ECT2, TIAM1, 
VAV1/2/3 and PREX1/2 (1,2). Increased expression and activation of these RhoGEFs result 
in enhanced activity of their Rho family small GTPase substrates in a context-dependent 
manner. For example, we recently identified overexpression of ECT2 protein in ovarian 
cancer, mediated by gene amplification, that resulted in activation of RHOA in the cytosol 
and RAC1 in the nucleus (3). The critical importance of RAC1 in cancer cell migration and 
invasion (4) has further focused attention on the mechanisms regulating activators of RAC1, 
such as the Dbl family of RhoGEFs.
The highly related Dbl RhoGEFs PREX1 and PREX2 (56% overall amino acid identity), 
which are GEFs for RAC1 and other Rho family small GTPases such as CDC42 (5), have 
been implicated as cancer drivers in several tumor types. The first cancer-driving role for 
PREX1 was described in prostate cancer (6), where limited analyses of tumor tissue revealed 
elevated levels of PREX1 protein. PREX1 was also elevated in metastatic but not primary 
prostate tumor cell lines. Suppression of PREX1 by RNA interference in PC-3 human 
prostate cancer cells decreased the levels of activated RAC and impaired tumor cell 
migration and invasion in vitro. Conversely, ectopic expression of PREX1 stimulated RAC 
activation, and promoted metastatic but not primary tumor growth of CWR22Rv1 prostate 
tumor cells. A follow-up study identified a histone deacetylase (HDAC)-mediated increase 
in PREX1 gene transcription as a basis for the increased levels of PREX1 protein in prostate 
cancer (7).
PREX1 overexpression was also identified in estrogen receptor-positive luminal and HER2-
positive breast cancers (8-10). PREX1 protein was detected in ~60% of breast tumors but 
not in normal breast tissue. PREX1 is located in a chromosomal region frequently amplified 
in breast cancers and PREX1 gene amplification was detected in breast cancer cell lines, 
supporting gene amplification as a mechanism for PREX1 protein overexpression in these 
tumor types. Silencing of PREX1 expression by RNA interference reduced HER2-stimulated 
activation of RAC1, and impaired tumor cell motility and invasion in vitro and tumorigenic 
growth in vivo (8-10).
A role in cancer for the related RhoGEF PREX2 has also been identified, but not by 
overexpression. Instead, missense mutations in PREX2 have been identified in 25% of 
malignant melanomas (11). Although no clear mutational hotspots have been seen in 
melanomas, experimental studies support a gain-of-function consequence of these mutations 
(11,12). PREX2 missense mutations have also been found in 38% of cutaneous squamous 
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cell carcinomas (13) and 17% of stomach adenocarcinomas (14). To date, a similar level of 
activating missense mutations in PREX1 in cancer has not been reported. However, the 
occurrence of activating missense mutations (e.g., P29S) in the PREX1 substrate, RAC1, in 
~11% of melanomas (15,16) is also consistent with a driver role for overexpressed PREX1 
in this disease.
Our previous studies revealed overexpression of PREX1 protein in melanoma cell lines and 
tumor tissue (17). Further, in a mouse model of melanoma, we determined that Prex1-
deficient mice were impaired in forming tumor metastases but not primary tumors. Here, 
extending our mouse model studies, we demonstrate that PREX1 protein is increased in 
human melanoma tumor tissue and that PREX1 is required for human melanoma cell 
invasion but not proliferation.
In a separate earlier study, we also identified PREX1 as a gene upregulated by the ERK 
mitogen-activated protein kinase (MAPK) in melanoma (18). The RAF-MEK-ERK protein 
kinase cascade is aberrantly activated in up to 80% of melanomas through BRAF or NRAS 
mutation, and serves as a critical therapeutic target in this disease (19-22). These 
observations supported the possibility that PREX1 protein overexpression in melanoma is 
driven by ERK activation. Additionally, since PREX1 has a demonstrated driver role in other 
cancers, PREX1 overexpression may be a key driver of ERK-dependent melanoma growth. 
In the present study, we determined that PREX1 protein overexpression is blocked by 
pharmacologic inhibitors of RAF-MEK-ERK signaling, and that ERK regulates not only 
PREX1 gene transcription but also PREX1 protein stability. Thus, there are significant 
cancer type-distinct mechanisms that drive PREX1 overexpression in cancer.
MATERIALS AND METHODS
Human melanoma tissue and immunohistochemistry (IHC)
Following institutional review board approval, primary and metastatic melanomas were 
retrieved from a series of patients treated at UNC Healthcare. Immunohistochemical staining 
was performed in the UNC Department of Dermatology Dermatopathology Laboratory as 
we have recently described (23). Briefly, freshly cut 4-μm thick sections of formalin-fixed 
and paraffin-embedded melanoma tissue blocks were stained using the fully automated 
Leica Bond III system. Sections were pretreated using an onboard heat-induced epitope 
retrieval in EDTA buffer. Following incubation with PREX1 antibody (6F12; provided by 
Marcus Thelen, IRB, Switzerland), chromogenic detection was performed using the Leica 
Refined Red polymer detection system (Leica Microsystems). Some sections were also 
counterstained with hematoxylin and eosin (H&E). PREX1 antibody staining intensity was 
scored in a blinded manner by a pathologist (AJ Finn) as high, medium, low or none.
Tissue culture
Cutaneous melanoma, breast cancer and prostate cancer cell lines were obtained from 
ATCC. Cells were maintained in Dulbecco's Modified Eagle Medium (DMEM) 
supplemented with 10% fetal bovine serum (FBS), and were not cultured for longer than 6 
months after receipt from cell banks.
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siRNA transfection, proliferation, and invasion assays
For siRNA knockdown, A375, WM2664, SK-MEL-119 and Mel224 cells were plated in 6-
well plates. Cells were transfected with 10 nM siRNA against PREX1 (Thermo Fisher 
s33364, s33365, s33366; PREX1 #1, #2, #3, respectively), RAC1 (Thermo Fisher s11711, 
s11712, s11713; RAC1 #1, #2, #3, respectively) or mismatch control (Dharmacon 
#D-001210-05), using Lipofectamine RNAimax (Life Technologies). Cells were serum-
starved overnight for 18 h and then seeded for invasion assays after 48 h of siRNA 
knockdown. For the proliferation assay, cells were seeded at 2-3 × 103 cells/well in 96-well 
plates and allowed to grow for 72 h before incubation for 3 h in 3-(4,5-dimethylthiazol-2-
yl)-2,5-diphenyltetrazolium bromide (MTT). MTT was solubilized in DMSO and the 
absorbance was read at A570. For the Boyden chamber invasion assay, 1-3 × 104 cells were 
seeded into the upper chamber of Matrigel-coated invasion chambers in duplicate (Corning 
BioCoat) and allowed to invade towards 20% FBS in DMEM for 24 h. Invasion chambers 
were fixed and stained using a Diff-Quik staining kit (GE). Invasion chambers were imaged 
using a 10x objective lens on a Nikon TS100 microscope at 5 fields per insert, and images 
were analyzed to calculate invaded cells per field using ImageJ software. For the collagen 
spheroid invasion assay, we slightly modified a published protocol (24,25). Briefly, 5-10 × 
103 cells were seeded in ultra-low attachment round-bottomed 96-well plates (Corning) for 
96 h, a sufficient time for the cells to organize into spheroids. Spheroids were then 
transferred to 48-well plates and embedded in collagen (1 mg/ml rat-tail collagen, BD). 
Spheroids were imaged at 0 h and after 72 h of invasion using a 5x objective on a Nikon 
TS100 microscope. Total spheroid area was calculated as fold-change in area of 72 h 
outgrowth versus 0 h spheroid area, using ImageJ.
Pulldown assay to detect GTPase activity
Levels of active, GTP-bound RAC1 and CDC42 were assessed by an affinity pulldown assay 
as we described previously (26). Briefly, after 48 h of siRNA-mediated PREX1 knockdown, 
whole cell lysates were exposed to GST-PAK-PBD, which contains the binding domain of 
the shared RAC1/CDC42 effector PAK1. After resolving pulldown samples on 15% SDS-
PAGE gels and western blotting for RAC1 (clone 23A9, BD) and CDC42 (BD), levels of 
each GTP-bound GTPase were normalized to both total protein and the vinculin loading 
control (Sigma) by densitometry analysis performed in ImageJ.
Drug treatment and western blotting
BRAF-mutant A375 and WM2664 cells were treated with BRAF inhibitor vemurafenib 
(Selleckchem) or ERK inhibitor SCH772984 (Merck, kindly provided by Ahmed Samatar), 
and NRAS-mutant SK-MEL-119 and Mel224 cells were treated with MEK inhibitor 
trametinib (Selleckchem) or SCH772984 for 24 and 48 h before samples were collected in 
RIPA lysis buffer. For PREX1 protein stability experiments, cells were co-treated with 
cycloheximide (50 μg/ml) and SCH772984 for a 24 h timecourse before samples were 
collected in RIPA. Whole cell lysates were resolved on 10% SDS-PAGE gels and western 
blotting was performed using antibodies to phospho-ERK1/2 (Thr202/Tyr204), total 
ERK1/2, phospho-RSK (Ser308), phospho-RSK (Thr359/Ser363), total RSK1/2/3, and c-
myc (MYC) (Cell Signaling); β-actin and vinculin (Sigma), and PREX1 (6F12) (27). 
Ryan et al. Page 4
Mol Cancer Res. Author manuscript; available in PMC 2017 October 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
IRDye800-conjugated anti-mouse and anti-rabbit secondary antibodies were from Rockland 
Immunochemicals.
Quantitative PCR
Total RNA was isolated using an RNeasy kit (Qiagen) and reverse transcription was 
performed using the High Capacity RNA-to-cDNA kit (Thermo Fisher). Real time 
quantitative Taqman PCR was performed on the QuantStudio 6 Flex (Thermo Fisher) with 
FAM/MGB labeled probes against PREX1 (Hs00368207_m1, Hs_001031512, Thermo 
Fisher) and endogenous control VIC/TAMRA labeled β-actin (Thermo Fisher).
Statistical analysis
Data were analyzed using GraphPad Prism 6 software and statistical analyses were 
performed as indicated in the Figure Legends.
RESULTS
PREX1 overexpression is correlated with elevated ERK activation
We recently identified overexpression of PREX1 protein in melanomas, determined that 
Prex1 deficiency impaired mouse melanoblast migration in vivo, and demonstrated that 
Prex1 expression is required for metastasis in an Nras-mutant genetically engineered mouse 
model of cutaneous melanoma (17). Since our previous gene array analyses identified 
PREX1 as an ERK activation-dependent gene (18), here we assessed a relationship among 
BRAF and NRAS mutation status, ERK activation and PREX1 protein overexpression in 
human melanoma. We first investigated the expression of PREX1 in a panel of human 
melanoma cell lines that did or did not harbor BRAF or NRAS mutations. The majority of 
BRAF- (3 of 4) or NRAS- (3 of 4) mutant cell lines exhibited substantially higher PREX1 
protein expression when compared with normal melanocytes or with BRAF/NRAS wild 
type cell lines (Figure 1A). Generally, the level of activated, phosphorylated ERK (pERK) 
correlated with the level of PREX1. In our analyses, normal melanocytes may exhibit low 
pERK levels (18), or they may also display low PREX1 protein levels even in the presence 
of high pERK levels, as shown here.
We next utilized immunohistochemistry (IHC) to evaluate PREX1 protein expression and 
pERK levels in melanoma patient tissues. We first compared PREX1 expression in benign 
melanocytic nevi (n=35) and human melanoma tumors (n=33) (Figure 1B). A range of 
expression was seen in nevi, with ~75% expressing low-to-medium levels of PREX1. Since 
BRAF and NRAS mutations are found in a high percentage of nevi (28,29), it is not 
surprising to find PREX1 in nevi as well as in melanoma tissue. However, high level PREX1 
expression was detected only in melanomas (~10%, Figure 1B).
ERK can phosphorylate numerous substrates present in both the nucleus and the cytoplasm 
(30,31), few of which have been firmly linked to specific outcomes of ERK-mediated 
signaling. Melanoma responses to pharmacological inhibitors of the RAF-MEK-ERK 
pathway (e.g., clinically, to BRAF inhibition (32) and preclinically, to inhibitors of ERK 
dimerization (33,34)) correlated with suppression of cytoplasmic pERK. We therefore 
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evaluated the distribution of pERK in our human melanoma tissues, and found that levels of 
pERK were correlated with those of PREX1 both in the nucleus (Figure 1C) and in the 
cytoplasm (Figure 1D). Both nuclear and cytoplasmic ERK activity may contribute to 
increased expression of PREX1.
PREX1 regulates invasion in a complex manner in both BRAF- and NRAS-mutant 
melanoma cell lines
An unexpected observation in our studies of PREX1 function in a mouse model of 
melanoma was that Prex1 deficiency greatly impaired metastatic but not tumorigenic 
growth. This result contrasts with studies evaluating the role of PREX1 overexpression in 
human breast cancer cells, where stable shRNA-mediated suppression of PREX1 reduced 
their tumorigenic growth (8-10). We therefore compared the effect of PREX1 suppression in 
human melanoma cell lines on both proliferation and invasion in vitro.
To evaluate the role of PREX1 overexpression in cell growth, we first used three 
independent siRNAs to knock down PREX1 in two BRAF-mutant (A375 and WM2664) and 
two NRAS-mutant cell lines (SK-MEL-119 and Mel224) (Figure 2A, upper panels). We 
found that transient (72 h) suppression of PREX1 did not significantly reduce their 
proliferation in vitro (Figure 2A, lower panels), consistent with the lack of effect of Prex1 
deficiency on the growth of primary melanomas in mice. Next, we evaluated the role of 
PREX1 in invasion by analysis of invasion through Matrigel towards serum as a 
chemoattractant. We observed a surprisingly heterogeneous response to PREX1 knockdown 
that was independent of BRAF or NRAS mutational status. For example, the NRAS-mutant 
line SK-MEL-119 exhibited a 60-70% decrease in invasion upon knockdown of PREX1 
(p<0.0001, Figure 2B) whereas the BRAF-mutant cell line A375 conversely exhibited a ~2-
fold increase (p<0.001). In contrast, the already very low degree of directed invasion of the 
BRAF-mutant line WM2664 was unaffected by PREX1 knockdown. Similarly, the invasive 
NRAS-mutant cell line Mel224 was largely unaffected, despite efficient knockdown of 
PREX1. These data demonstrate that PREX1 plays a complex and variable role in directed 
invasion towards an attractant.
Next, we investigated the role of PREX1 in a three-dimensional spheroid formation and 
collagen invasion assay, which mimics the in vivo tumor environment of human skin (35). 
Figure 2C illustrates both spheroid formation and the subsequent invasion of cells from the 
spheroid into the surrounding collagen matrix. In three of the four cell lines, knockdown of 
PREX1 impaired spheroid invasion into collagen, either trending (SK-MEL-119) or 
significantly so (Mel224, WM2664). In contrast, A375 spheroids were defective in 
formation and did not invade the surrounding collagen matrix. The nearly doubled total 
spheroid area of PREX1-knockdown A375 cells compared to mismatch control cells 
observed after 4 days in culture was caused by a flattening of the three-dimensional spheroid 
structure and not by increased invasion or by increased proliferation; no change in 
proliferation occurred upon loss of PREX1 (Fig. 2A).
Collectively, our results suggest a complex and context-dependent role for PREX1 in driving 
both directed invasion and three-dimensional spheroid collagen outgrowth of human 
melanomas, and one that is not dependent on BRAF or NRAS mutational status.
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PREX1 regulates active, GTP-bound RAC1 but not CDC42 in melanoma cells
Although PREX1 is considered a RAC-selective GEF (36), PREX1 is also active on CDC42 
(27). We therefore investigated which Rho family small GTPases are activated downstream 
of PREX1 in human melanoma cells. We found that knockdown of PREX1 decreased the 
levels of activated RAC1, as measured by RAC1-GTP pulldown, in both BRAF-mutant 
A375 and NRAS-mutant SK-MEL-119 cells (Figure 3). Despite the continued presence of 
other RacGEFs capable of inducing nucleotide exchange on RAC1, even incomplete loss of 
PREX1 was sufficient to cause a substantial decrease in RAC1-GTP (Figure 3). This effect 
was selective for RAC1, as the levels of activated CDC42 did not decrease (Figure 3). These 
results support a role for PREX1 in regulating RAC1 activity and subsequent RAC1-driven 
invasive behavior of melanomas.
We next asked if the loss of RAC1 was sufficient to phenocopy the impairment of invasion 
that we observed upon loss of PREX1. We found that knockdown of either PREX1 or RAC1 
with three independent siRNAs for each (Figure 4A) was sufficient to substantially impair 
spheroid formation of A375 cells, as demonstrated by an increase in the flattened spheroid 
area (Figure 4B,C). The degree of impairment upon knockdown of RAC1 was highly 
significant (p<0.0001, Figure 4C) and comparable to the degree of impairment observed 
upon knockdown of PREX1 (p<0.0001, Figure 4C). Next, we observed that loss of RAC1 
(Figure 4D) was sufficient to prevent the vast majority of SK-MEL-119 cell invasion in the 
Boyden chamber assay (Figure 4E). This decrease in invasion was similar to the decrease 
seen upon PREX1 knockdown (p<0.0001, Figure 4F). The ability of RAC1 to phenocopy 
PREX1 in impairing both spheroid formation and directed invasion supports the idea that 
RAC1 is the most critical Rho family small GTPase downstream of PREX1 in regulating 
invasive melanoma behavior. Of note, other Rho family small GTPases such as RND3 have 
also been shown to be regulated by the RAF-MEK-ERK pathway and to contribute to 
melanoma invasion and spheroid outgrowth (37,38). However, as a Rho-like rather than a 
Rac-like GTPase, RND3 is unlikely to be a target of PREX1 in this context (39).
PREX1 protein levels are positively regulated by ERK activity in melanoma
Our evaluation of human melanoma cell lines and tumor tissue found a correlation between 
phosphorylated ERK and PREX1 protein overexpression. To directly address whether ERK 
activation is required for PREX1 overexpression, we evaluated whether pharmacologic 
inhibition of RAF-MEK-ERK signaling would reduce PREX1 protein levels in BRAF- and 
NRAS-mutant melanoma. We first treated NRAS-mutant SK-MEL-119 cells with increasing 
concentrations of the MEK inhibitor trametinib. The more effective the inhibition of MEK, 
as measured by decreasing levels of phosphorylated and activated ERK (pERK) and total 
MYC (an ERK substrate; ERK phosphorylation blocks degradation), the greater the decrease 
in PREX1 protein (Figures 5A,B), suggesting a direct correlation between ERK activity and 
PREX1 protein levels. We next wanted to determine whether this dose-dependent decrease 
in PREX1 protein would also occur when the ERK MAPK cascade was inhibited at different 
nodes, and whether such an effect is time-dependent. We therefore treated SK-MEL-119 
cells with two different concentrations (1 × EC50 and 5 × EC50 for growth) of either 
trametinib or the ERK inhibitor SCH772984, for either 24 or 48 h (Figures 5C,D). PREX1 
protein levels tracked closely with the level of pERK at each concentration of inhibitor, and 
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this was sustained for 48 h. Next, we investigated whether PREX1 protein was similarly 
regulated downstream of the ERK-MAPK cascade in BRAF-mutant melanoma cells. We 
treated A375 cells similarly but with the BRAF inhibitor vemurafenib or SCH772984 for 24 
or 48 h (Figures 5E,F). Similarly to SK-MEL-119 cells, levels of PREX1 in A375 cells 
tracked closely with the levels of pERK and demonstrated a time-dependent effect. In both 
SK-MEL-119 and A375 cells, phosphorylation of the ERK substrate RSK (pRSK) and total 
MYC served as effective markers to demonstrate inhibition of ERK, as we have observed in 
other settings (40). These results indicate that ERK MAPK activity is an important 
contributor to the total amount of PREX1 protein in melanoma cells.
PREX1 levels are regulated by ERK both transcriptionally and post-transcriptionally in 
melanoma
To determine if the loss of PREX1 protein upon blockade of the ERK MAPK cascade was 
due to loss of PREX1 mRNA, we treated two BRAF-mutant and two NRAS-mutant 
melanoma cell lines with ERK MAPK cascade inhibitors. BRAF-mutant A375 and 
WM2664 cells were treated for 24 h with vemurafenib or SCH772984 as above. Taqman 
quantitative PCR analysis revealed that PREX1 mRNA, measured by two independent 
probes, did not change upon inhibition of BRAF or ERK in A375 cells (Figure 6A) but 
decreased dose-dependently in WM2664 cells upon inhibition of either BRAF or ERK 
(Figure 6B). NRAS-mutant cells were treated with trametinib or SCH772984 as above. We 
observed that PREX1 mRNA also decreased upon ERK inhibition in both SK-MEL-119 
(Figure 6C) and Mel224 cells (Figure 6D). Additional melanoma lines also exhibited 
reduced PREX1 mRNA levels when treated with inhibitors of the ERK MAPK cascade, 
including BRAF-mutant SK-MEL-28 and NRAS-mutant SK-MEL-147 cells (Figures 
S3A,B). Thus, in the majority of melanoma cell lines, ERK MAPK regulates PREX1 protein 
levels both transcriptionally and post-transcriptionally.
That ERK MAPK activity altered PREX1 protein levels in A375 melanoma cells without 
changes at the transcriptional level suggested a post-transcriptional mechanism for ERK 
MAPK-mediated regulation of PREX1 protein in these cells. To investigate this possibility, 
we treated A375 cells with vehicle or SCH772984 in the presence of the protein synthesis 
inhibitor cycloheximide at various time points over 24 h (Figures 6E,F). Inhibition of ERK 
led to greater loss of PREX1 protein in the presence of cycloheximide compared to vehicle-
treated cells. Similar results were obtained upon treatment of SK-MEL-119 cells with 
trametinib in the presence of cycloheximide (Figures S3C,D). These results indicate that 
ERK can regulate protein stability as well as transcription of PREX1 in melanoma cell lines.
Finally, we tested the possibility that PREX1 is not only an ERK target but also an ERK 
activator. Since it has been demonstrated that PREX1 can regulate MEK-ERK signaling 
through RAC1 in breast cancer (8,41), we also examined whether PREX1 can regulate 
ERK1/2 phosphorylation in our melanoma lines. We found that knockdown of PREX1 did 
not alter ERK1/2 phosphorylation in the BRAF-mutant cell lines, A375 and WM2664, or the 
NRAS-mutant cell lines, SK-MEL-119 and Mel224 (Figures S4A,B and S4C,D, 
respectively).
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To determine the generality of ERK regulation of PREX1 expression in no-nmelanoma 
tumor types, we also tested whether they held true in breast and prostate cancer cell lines. 
PREX1 has been shown to be overexpressed in these tumor types, but the role of ERK in its 
expression has not been explored. Unlike our observations in melanoma cells, we observed 
that inhibition of the ERK MAPK cascade in T47D and MCF7 breast cancer cells did not 
reduce PREX1 protein (Figures S5A,C) or mRNA (Figures S5B,D). Conversely, in PC-3 
prostate cancer cells, inhibition of the ERK MAPK cascade reduced PREX1 mRNA levels 
(Figure S5F) but had minimal effects on PREX1 protein (Figure S5E). These results support 
distinct mechanisms of regulating PREX1 expression in melanoma through ERK1/2 that do 
not apply in breast or prostate cancer, cancers in which BRAF and RAS mutation 
frequencies are low. Overall, our results support that both ERK regulation of PREX1 
abundance and PREX1 regulation of ERK phosphorylation are context-dependent, and may 
differ between breast and prostate cancers and cutaneous melanoma.
DISCUSSION
We determined that the ERK MAPK cascade plays an important role in driving PREX1 
protein overexpression in both BRAF- and NRAS-mutant melanomas. In contrast, ERK is 
not the key driver for PREX1 overexpression in prostate (6,7) or in breast carcinomas 
(8-10,42), where its abundance is associated with HDAC-dependent (7) PREX1 gene 
transcription and with HDAC- and methylation-dependent PREX1 gene transcription (42) 
and gene amplification (8,10,42), respectively. Thus, there are striking cancer-type 
differences in mechanisms driving PREX1 overexpression. In support of this idea, PREX1 
and PREX2 display distinct expression and mutation patterns in breast cancer, prostate 
cancer, and melanoma (Figure S1), and PREX1 in particular is differentially amplified in 
breast cancer, prostate cancer and cutaneous melanoma (Figure S2). Our findings also 
suggest that loss of PREX1-RAC1 signaling may contribute to the clinical response of 
patients with BRAF-mutant melanomas to BRAF and MEK inhibitors.
The effectiveness of these inhibitors provides compelling evidence that aberrant ERK 
signaling is a major driver of melanoma growth. Despite this clear driver role, the ERK 
targets important for melanoma growth remain poorly characterized. The ERK1/2 kinases 
can phosphorylate more than 200 known substrates (30,31) and serve as master regulators of 
numerous transcription factors (43), both directly and indirectly, through both transcriptional 
and post-translational mechanisms (40,43-45) We have determined that ERK regulates 
PREX1 expression levels in part via protein stability, a mechanism also not observed in 
other cancers. ERK regulation of PREX1 protein stability presents a previously unknown 
mechanism of maintaining PREX1 protein expression and may explain the basis for the 
relatively high PREX1 expression in malignant melanomas where the ERK MAPK cascade 
is upregulated.
Finally, the PREX1-related RhoGEF PREX2 is activated by missense mutations in 25% of 
metastatic melanomas, especially by truncating mutations mutations (11,12), and mutational 
activation of the PREX1/2 target RAC1 has been observed in ~11% of melanomas (15,16). 
The rarity of PREX1 truncating mutations and lack of apparent hotspots among the few 
missense mutations argue that this is not a significant mechanism of PREX1 activation in 
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melanoma. Instead, our determination that PREX1 is overexpressed and regulated at 
multiple levels in response to the ERK MAPK cascade characterizes a third mechanism for 
driving aberrant RAC1 signaling in melanoma. Our findings that loss of RAC1 phenocopies 
loss of PREX1 with respect to invasive behavior regardless of BRAF or NRAS mutation 
status supports the importance of the PREX1-RAC1 relationship as a promoter of melanoma 
cell invasion. Interestingly, downregulation of the RacGEF TIAM1 by mutant BRAF was 
shown to enhance invasion of human melanoma cells (46). Although PREX1 was not 
examined in that particular study, PREX1 has consistently demonstrated a positive role in 
invasion (6,17,47), whereas TIAM1 can be either a positive or a negative regulator of this 
process (1,46,48-50). Thus, the relative input from different upstream activators of RAC1 
can have a profound influence on melanoma invasion.
In summary, we have demonstrated that the ERK MAPK cascade mediates overexpression 
of PREX1 in melanoma at multiple levels, and by mechanisms that are distinct from those 
identified previously in other cancer types. Our results contribute to a better understanding 
of how RacGEFs are modulated in distinct cancer contexts.
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Figure 1. PREX1 protein levels are elevated in melanoma patient tumor tissues and cell lines, 
along with phospho-ERK
(A) Western blot analysis of PREX1 protein, phospho-ERK (pERK) and total ERK1/2 in a 
panel of WT, BRAF- or NRAS-mutant human melanoma tumor cell lines. (B-D) Human 
tissue samples of benign melanocytic nevi and malignant skin cutaneous melanoma were 
subjected to IHC for PREX1 and pERK. Shown are (B) the distribution of PREX1 
expression in nevi versus melanoma samples as measured by IHC; n=35 and 33, 
respectively. Samples were first binned according to no, low, medium or high staining 
intensity for each protein, and then the distribution was graphed to show the relationship 
between PREX1 and the percent of samples that stained positive for (C) nuclear pERK or 
(D) cytoplasmic pERK.
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Figure 2. PREX1 regulates spheroid formation and invasion, but not proliferation, of BRAF- and 
NRAS-mutant melanoma cells in a context-dependent manner
(A) BRAF-mutant A375 and WM2664 and NRAS-mutant SK-MEL-119 and Mel224 cells 
were transfected with siRNA against PREX1 or a mismatch control (MM) for 48 h, and 
knockdown was confirmed by western blot (upper panels). Apparent molecular weights are 
indicated to the right of each panel; vinculin served as a loading control. Fold changes in 
protein expression compared to MM control are shown in numbers below each blot. Effects 
of PREX1 knockdown on growth in monolayer culture were determined by MTT assay at 72 
hr (lower panels). (B) To determine the effects of PREX1 knockdown on invasion, cells were 
seeded in the upper chamber of a Matrigel-coated Boyden chamber, and allowed to invade 
towards serum for 24 h, then stained and imaged. ImageJ was used to quantitate invaded 
cells per field for 5 fields per insert in duplicate inserts (A375, SK-MEL-119, Mel224) or 
invaded cells over both inserts (WM2664). (C) For spheroid collagen invasion assays, 
spheroids were allowed to form for 4 days. Total spheroid area was normalized to that of 
mismatch control-treated cells; impaired spheroid formation is indicated by increased area of 
the flattened spheroid. WM2664, SK-MEL-119, and Mel224 spheroids were embedded in a 
collagen matrix and imaged (day 0) and the extent of cell outgrowth/invasion was imaged 3 
days later (thick gray lines). Fold change in area from day 3 to day 0 was calculated in 
ImageJ. Data are represented as mean ± SD and statistical significance was evaluated by 
Student's t-test, where *: p<0.05, **: p<0.01, ***: p<0.001, ****: p<0.0001. Scale bar 
represents 250 μm for invasion assays and 500 μm for spheroids. Experiments shown are 
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representative of two (WM2664, SK-MEL-119) or three (A375, SK-MEL-119) independent 
experiments.
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Figure 3. PREX1 regulates active RAC1-GTP, but not active CDC42-GTP, in melanoma cells
A375 and SK-MEL-119 cells were transfected with pooled siRNAs #1-3 against PREX1 or 
MM control for 48 h, then starved overnight (18 h). RAC1-GTP and CDC42-GTP were 
measured by GST-PAK-PBD pulldown (A). Apparent molecular weights are indicated to the 
right of each panel; vinculin served as a loading control. Quantification (mean ± SD) using 
ImageJ (B) is representative of two independent experiments.
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Figure 4. RAC1 phenocopies PREX1 in regulating spheroid formation in A375 and invasion in 
SK-MEL-119
A375 and SK-MEL-119 cells were transfected with siRNA against PREX1, RAC1, or MM 
control for 48 h before seeding into invasion chambers. Knockdown was confirmed by 
western blot in A375 (panel A) and SK-MEL-119 (panel D). Apparent molecular weights 
are on the right of each panel; vinculin was a loading control. Total spheroid area of A375 
cells was quantified after 4 days using ImageJ (white line); increased flattened spheroid area 
indicates impaired spheroid formation (panels B,C). SK-MEL-119 cells were starved 
overnight and seeded in a Boyden chamber assay with 20% serum as a chemoattractant and 
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allowed to invade for 24h (10x magnification) (E). Stained inserts were quantified for 
invaded cells/field, 10 fields per condition, using ImageJ (F). Data are represented as mean ± 
SD. Student's t-test, where *: p<0.05, **: p<0.01, ***: p<0.001, ****: p<0.0001). Scale bar 
represents 250 μm for invasion assays and 500 μm for spheroids.
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Figure 5. PREX1 protein levels are regulated by the ERK kinase cascade
NRAS-mutant SK-MEL-119 cells were first treated with the indicated concentrations of 
MEKi trametinib for 48 h, and lysates immunoblotted for PREX1, pERK and MYC (A; 
quantified in B). SK-MEL-119 cells were next treated with trametinib or the ERK inhibitor 
SCH772984 for 24 or 48 h, and lysates probed for pERK and PREX1 (C; quantified in D), 
and for pRSK and total MYC to monitor ERK pathway inhibition (C). Similarly, BRAF-
mutant A375 cells were treated with the BRAF inhibitor vemurafenib or with SCH772984 
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for 24 or 48 h and lysates probed as above (E; quantified in F). Quantification is of n=3 
experiments for SK-MEL-119 and n=4 for A375. Data are represented as mean ± SD.
Ryan et al. Page 22
Mol Cancer Res. Author manuscript; available in PMC 2017 October 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Figure 6. PREX1 levels are regulated by ERK both transcriptionally and post-transcriptionally
BRAF-mutant A375 and WM2664 cells were treated with vemurafenib or SCH772984 for 
24 h and PREX1 mRNA levels were measured by Taqman qPCR using two independent 
probes (A,B). NRAS-mutant SK-MEL-119 and Mel224 cells were treated with trametinib or 
SCH772984 for 24 h, and PREX1 mRNA measured as above (C,D). Taqman analyses 
indicate compiled results of n=2 experiments for WM2664 and Mel224, and n=3 
experiments for A375 and SK-MEL-119. To test posttranscriptional regulation, A375 cells 
were treated with vehicle or SCH772984 in the presence of 50 μg/ml cycloheximide, and 
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lysates were probed by western blot for PREX1, pERK and MYC (E). Quantification of 
PREX1 levels using ImageJ (F) is representative of n=2 independent experiments. Data are 
represented as mean ± SD.
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